Alzamend Neuro, Inc.
Close on Oct 19, 2026
- Market cap
- $5.96M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Apr 30, 2025 | Jul 23, 2025 | After market close | – | – | – |
| Q3 FY2023 Ended Jan 31, 2023 | Mar 16, 2023 | After market close | – | $-0.06 | – |
Press releases
Announcements Alzamend Neuro filed with the SEC
9 PHANTOM VALIDATION Lithium image spatial resolution of 3D radial bSSFP
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Reports Annual 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Alzamend Neuro Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Reports Second Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Alzamend Neuro Regains Compliance with Nasdaq
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Regains Compliance with Nasdaq’s
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Announces Favorable Decision
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro, Inc. Corporate Presentation May 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Announces Agreement for Registered Direct
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Announces Termination of At-the-Market
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Announces Positive Phase IIA
Regulation FD disclosure · EX-99 to Form 8-K
Alzamend Neuro, Inc. Corporate Presentation April 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Announces the Initiation of
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Announces Completion of Clinical Portion of
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Reports Third Fiscal Quarter
Results of operations · EX-99.1 to Form 8-K
Alzamend Neuro, Inc. Corporate Presentation January 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro, Inc. Corporate Presentation November 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Receives FDA “Study May
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
Regulation FD disclosure · EX-99.1 to Form 8-K
Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Has Regained Compliance
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro, Inc. Corporate Presentation August 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro, Inc. Corporate Presentation June 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro, Inc. Corporate Presentation April 2022
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K/A
Alzamend Neuro, Inc. Corporate Presentation April 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Alzamend Neuro Announces Positive Topline Data
Regulation FD disclosure · EX-99.1 to Form 8-K